CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors are considered as a revolution for patients with advanced NSCLC and became a therapeutic standard for NSCLC without oncogenic addiction in European and US Guidelines regardless of PDL1 expression [46, 47].